152 related articles for article (PubMed ID: 19216123)
1. American Society of Hematology--50th Annual Meeting and Exposition--Part 1.
Scattereggia J; Millar E
IDrugs; 2009 Feb; 12(2):63-5. PubMed ID: 19216123
[No Abstract] [Full Text] [Related]
2. The American Society of Hematology--46th Annual Meeting and Exposition. Drug highlights II.
Evans L
IDrugs; 2005 Jan; 8(1):10-3. PubMed ID: 15650933
[No Abstract] [Full Text] [Related]
3. American Society of Hematology--51st annual meeting & exposition. Part 1.
Shumoogam J; Beecher N
IDrugs; 2010 Feb; 13(2):57-9. PubMed ID: 20127549
[TBL] [Abstract][Full Text] [Related]
4. American Society of Hematology--50th Annual Meeting and Exposition--Part 2.
Cleverley J; Millar E
IDrugs; 2009 Feb; 12(2):66-8. PubMed ID: 19216125
[No Abstract] [Full Text] [Related]
5. The 50th Annual Meeting of the American Society of Hematology.
Cunningham S; Muneer S
Clin Lymphoma Myeloma; 2009 Jun; 9(3):197-205. PubMed ID: 19525188
[No Abstract] [Full Text] [Related]
6. American society of hematology-45th annual meeting and exposition: hematological malignancies.
Davies J
IDrugs; 2004 Jan; 7(1):1-3. PubMed ID: 14968766
[No Abstract] [Full Text] [Related]
7. Marching against blood diseases: a report from the 51st Annual Meeting of the American Society of Hematology (December 5-8, 2009 - New Orleans, Lousiana, USA).
Rabasseda X
Drugs Today (Barc); 2010 Mar; 46(3):195-230. PubMed ID: 20467593
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy for haematological malignancies: clinical update from the American Society of Hematology, 2004.
Haas M; Lonial S
Expert Opin Investig Drugs; 2005 Sep; 14(9):1161-9. PubMed ID: 16144500
[TBL] [Abstract][Full Text] [Related]
9. American Society of Hematology--47th annual meeting and exposition.
Murch L
IDrugs; 2006 Feb; 9(2):84-6. PubMed ID: 16523392
[No Abstract] [Full Text] [Related]
10. American Society of Hematology--48th Annual Meeting and Exposition. Therapeutic approaches for hematological cancers. 9-12 December 2006 Orlando, FL, USA.
Tear S
IDrugs; 2007 Feb; 10(2):84-6. PubMed ID: 17285454
[No Abstract] [Full Text] [Related]
11. A derivative of epigallocatechin-3-gallate induces apoptosis via SHP-1-mediated suppression of BCR-ABL and STAT3 signalling in chronic myelogenous leukaemia.
Jung JH; Yun M; Choo EJ; Kim SH; Jeong MS; Jung DB; Lee H; Kim EO; Kato N; Kim B; Srivastava SK; Kaihatsu K; Kim SH
Br J Pharmacol; 2015 Jul; 172(14):3565-78. PubMed ID: 25825203
[TBL] [Abstract][Full Text] [Related]
12. [Programs for continuing medical education: B session 7. Progress in treatment for hematologic diseases].
Higashihara M
Nihon Naika Gakkai Zasshi; 2014 Mar; 103(3):717-23. PubMed ID: 24796142
[No Abstract] [Full Text] [Related]
13. [48th World Congress of the American Society of Hematology].
L'Allemain G;
Bull Cancer; 2007 May; 94(5):489-94. PubMed ID: 17535788
[No Abstract] [Full Text] [Related]
14. American Society of Hematology--48th Annual Meeting and Exposition. Updates on hematological therapies. 9-12 December 2006 Orlando, FL, USA.
Walker K
IDrugs; 2007 Feb; 10(2):78-80. PubMed ID: 17285452
[No Abstract] [Full Text] [Related]
15. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
[TBL] [Abstract][Full Text] [Related]
16. American society of hematology-45th annual meeting and exposition symposia.
Davies J
IDrugs; 2004 Jan; 7(1):4-6. PubMed ID: 14968768
[No Abstract] [Full Text] [Related]
17. A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells.
Chen CW; Lee YL; Liou JP; Liu YH; Liu CW; Chen TY; Huang HM
Apoptosis; 2016 Sep; 21(9):1008-18. PubMed ID: 27344662
[TBL] [Abstract][Full Text] [Related]
18. Chronic myeloid leukemia--some topical issues.
Mughal T; Cortes J; Cross NC; Donato N; Hantschel O; Jabbour E; Kantarjian H; Melo JV; Skorski T; Silver RT; Goldman JM
Leukemia; 2007 Jul; 21(7):1347-52. PubMed ID: 17495971
[No Abstract] [Full Text] [Related]
19. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
